{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:59:57Z","timestamp":1793386797314,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"12","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001064"],"award-info":[{"award-number":["UL1TR001064"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11,29]]},"DOI":"10.1093\/cid\/cix696","type":"journal-article","created":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T11:08:43Z","timestamp":1501844923000},"page":"2000-2007","source":"Crossref","is-referenced-by-count":51,"title":["Role of Secondary Prophylaxis With Valganciclovir in the Prevention of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients"],"prefix":"10.1093","volume":"65","author":[{"given":"Bradley J","family":"Gardiner","sequence":"first","affiliation":[{"name":"Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center and Tufts University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K","family":"Chow","sequence":"additional","affiliation":[{"name":"Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center and Tufts University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori Lyn","family":"Price","sequence":"additional","affiliation":[{"name":"Institute for Clinical Research and Health Policy Studies, Tufts Medical Center"},{"name":"Tufts Clinical and Translational Science Institute, Tufts University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie E","family":"Nierenberg","sequence":"additional","affiliation":[{"name":"Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center and Tufts University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Kent","sequence":"additional","affiliation":[{"name":"Tufts Clinical and Translational Science Institute, Tufts University"},{"name":"Predictive Analytics and Comparative Effectiveness Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Snydman","sequence":"additional","affiliation":[{"name":"Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center and Tufts University School of Medicine"},{"name":"Tufts Clinical and Translational Science Institute, Tufts University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,8,7]]},"reference":[{"key":"key\n\t\t\t\t20180306232520_CIT0001","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/ajt.12103","article-title":"Cytomegalovirus in solid organ transplantation","volume":"13 Suppl 4","author":"Razonable","year":"2013","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20180306232520_CIT0002","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1600-6143.2009.02617.x","article-title":"Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients","volume":"9","author":"Asberg","year":"2009","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20180306232520_CIT0003","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1600-6143.2007.01910.x","article-title":"Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients","volume":"7","author":"Asberg","year":"2007","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20180306232520_CIT0004","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","article-title":"Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"96","author":"Kotton","year":"2013","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20180306232520_CIT0005","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/j.1600-6143.2010.03114.x","article-title":"Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients","volume":"10","author":"Asberg","year":"2010","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20180306232520_CIT0006","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-6143.2009.02861.x","article-title":"Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients","volume":"10","author":"Eid","year":"2010","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20180306232520_CIT0007","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1086\/514555","article-title":"Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group","volume":"25","author":"Falagas","year":"1997","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306232520_CIT0008","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/j.1432-2277.2011.01321.x","article-title":"The risk of cytomegalovirus recurrence after kidney transplantation","volume":"24","author":"Helanter\u00e4","year":"2011","journal-title":"Transpl Int"},{"key":"key\n\t\t\t\t20180306232520_CIT0009","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/tid.12247","article-title":"Current characteristics and outcome of cytomegalovirus infections after kidney transplantation","volume":"16","author":"Helanter\u00e4","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"key\n\t\t\t\t20180306232520_CIT0010","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00007890-199901150-00016","article-title":"Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients","volume":"67","author":"Humar","year":"1999","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20180306232520_CIT0011","first-page":"231","article-title":"Prevalence and risk factors of recurrent cytomegalovirus infection in kidney transplant recipients","volume":"8","author":"Nafar","year":"2014","journal-title":"Iran J Kidney Dis"},{"key":"key\n\t\t\t\t20180306232520_CIT0012","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/TP.0b013e31828ee12e","article-title":"International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines","volume":"95","author":"Le Page","year":"2013","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20180306232520_CIT0013","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1097\/TP.0b013e3181ff1493","article-title":"Extended valganciclovir prophylaxis in D+\/R\u2013 kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study","volume":"90","author":"Humar","year":"2010","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20180306232520_CIT0014","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20180306232520_CIT0015","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.transproceed.2009.06.005","article-title":"Prophylactic therapy with valganciclovir in high-risk (cytomegalovirus D+\/R\u2013) liver transplant recipients: a single-center experience","volume":"41","author":"Montejo","year":"2009","journal-title":"Transplantat Proc"},{"key":"key\n\t\t\t\t20180306232520_CIT0016","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1681\/ASN.2008111166","article-title":"Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection","volume":"20","author":"Luan","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180306232520_CIT0017","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(05)66553-1","article-title":"Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials","volume":"365","author":"Hodson","year":"2005","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180306232520_CIT0018","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1086\/507337","article-title":"Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies","volume":"43","author":"Small","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306232520_CIT0019","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1034\/j.1399-3062.2000.020102.x","article-title":"Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir","volume":"2","author":"Turgeon","year":"2000","journal-title":"Transpl Infect Dis"},{"key":"key\n\t\t\t\t20180306232520_CIT0020","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1399-0012.1998.tb01103.x","article-title":"Maintenance therapy with oral ganciclovir after treatment of cytomegalovirus infection","volume":"12","author":"Nankivell","year":"1998","journal-title":"Clin Transplant"},{"key":"key\n\t\t\t\t20180306232520_CIT0021","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/TP.0000000000000386","article-title":"The role of secondary cytomegalovirus prophylaxis for kidney and liver transplant recipients","volume":"99","author":"Sullivan","year":"2015","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20180306232520_CIT0022","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/TP.0000000000001338","article-title":"Recurrence of CMV infection and the effect of prolonged antivirals in organ transplant recipients","volume":"101","author":"Natori","year":"2017","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20180306232520_CIT0023","volume-title":"Valcyte (valganciclovir), package insert","author":"Genentech","year":"2015"},{"key":"key\n\t\t\t\t20180306232520_CIT0024","volume-title":"Cytovene (ganciclovir), package insert","author":"Genentech","year":"2016"},{"key":"key\n\t\t\t\t20180306232520_CIT0025","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180306232520_CIT0026","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1086\/339329","article-title":"Definitions of cytomegalovirus infection and disease in transplant recipients","volume":"34","author":"Ljungman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306232520_CIT0027","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1086\/425002","article-title":"The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients","volume":"39","author":"Munoz-Price","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306232520_CIT0028","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/lt.23991","article-title":"Pretransplant lymphopenia is a novel prognostic factor in cytomegalovirus and noncytomegalovirus invasive infections after liver transplantation","volume":"20","author":"Nierenberg","year":"2014","journal-title":"Liver Transpl"},{"key":"key\n\t\t\t\t20180306232520_CIT0029","doi-asserted-by":"crossref","first-page":"984","DOI":"10.7326\/0003-4819-119-10-199311150-00004","article-title":"Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial","volume":"119","author":"Snydman","year":"1993","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180306232520_CIT0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306232520_CIT0031","first-page":"34","article-title":"Recurrent cytomegalovirus disease in solid-organ transplant recipients","volume":"27","author":"Falagas","year":"1995","journal-title":"Transplantat Proc"},{"key":"key\n\t\t\t\t20180306232520_CIT0032","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1093\/eurheartj\/ehv252","article-title":"Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis","volume":"36","author":"Kent","year":"2015","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180306232520_CIT0033","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2016.16435","article-title":"Confounding by indication in clinical research","volume":"316","author":"Kyriacou","year":"2016","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180306232520_CIT0034","doi-asserted-by":"crossref","first-page":"f6409","DOI":"10.1136\/bmj.f6409","article-title":"Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research","volume":"347","author":"Freemantle","year":"2013","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180306232520_CIT0035","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jama.2015.13480","article-title":"The propensity score","volume":"314","author":"Haukoos","year":"2015","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180306232520_CIT0036","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.2014.4364","article-title":"Can the learning health care system be educated with observational data?","volume":"312","author":"Dahabreh","year":"2014","journal-title":"JAMA"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/65\/12\/2000\/24267136\/cix696.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T20:32:13Z","timestamp":1750797133000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/65\/12\/2000\/4070503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,7]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,8,7]]},"published-print":{"date-parts":[[2017,11,29]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cix696","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,12,15]]},"published":{"date-parts":[[2017,8,7]]}}}